Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update [Yahoo! Finance]
Revance Therapeutics, Inc. (RVNC)
Last revance therapeutics, inc. earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.revance.com
Company Research
Source: Yahoo! Finance
– Q4 DAXXIFY volume up 22% over Q3 2023, with over two-thirds of Q4 revenue attributable to reordering accounts. – 2024 product revenue guidance of at least $280 million, supporting blockbuster potential in U.S. aesthetics. – DAXXIFY for cervical dystonia on track for commercial launch mid-year; Permanent J-Code for DAXXIFY received January 2024. – 2023 GAAP and non-GAAP OPEX on the low end of previously announced guidance ranges; 2024 GAAP and non-GAAP OPEX guidance of $460 million to $490 million and $290 million to $310 million, respectively. – Cash, cash equivalents and short-term investments of $253.9 million as of December 31, 2023; Management anticipates achieving positive Adjusted EBITDA in 2025. – Conference call and webcast today at 4:30 p.m. ET. NASHVILLE, Tenn., February 28, 2024 BUSINESS WIRE Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
Show less
Read more
Impact Snapshot
Event Time:
RVNC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVNC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVNC alerts
High impacting Revance Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RVNC
News
- Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 [Yahoo! Finance]Yahoo! Finance
- Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024Business Wire
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Revance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the company [Yahoo! Finance]Yahoo! Finance
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingBusiness Wire
RVNC
Earnings
- 2/28/24 - Beat
RVNC
Sec Filings
- 5/3/24 - Form 8-K
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- RVNC's page on the SEC website